Related Experiment Video
Updated: Jun 11, 2026
09:44
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Crohn's disease as an immunodeficiency
Bu'Hussain Hayee1, Farooq Z Rahman, Gavin Sewell
1Department of Molecular Medicine, University College London, London, WC1E 6JJ, UK. b.hayee@nhs.net
Expert Review of Clinical Immunology
|July 3, 2010
Summary
Crohn's disease (CD) may stem from a primary immunodeficiency, not just T-cell issues. This innate immune defect explains the characteristic inflammation, opening new therapeutic avenues for CD patients.
Area of Science:
- Immunology
- Gastroenterology
- Genetics
Background:
- Crohn's disease (CD) pathogenesis traditionally viewed as T-cell dysregulation.
- Focus has been on chronic inflammation, overlooking potential primary immune defects.
Purpose of the Study:
- Re-evaluate CD pathogenesis, proposing a primary immunodeficiency model.
- Investigate the link between innate immune defects and granulomatous inflammation in CD.
- Identify novel therapeutic and diagnostic targets for Crohn's disease.
Main Methods:
- Review of molecular biological and clinical investigations.
- Analysis of genome-wide association studies (GWAS) data.
- In vitro and in vivo immune system stimulation studies.
Main Results:
- Evidence suggests CD is a primary immunodeficiency.
- Innate immune dysfunction is implicated in CD pathogenesis, though heritable risk is <20%.
- Immune stimulation studies reveal new insights into disease mechanisms.
Conclusions:
- CD pathogenesis may involve a primary defect in the innate immune system.
- This defect mechanistically links to the granulomatous inflammation seen in CD.
- Novel therapeutic and diagnostic strategies for CD can emerge from understanding innate immunity.
Related Concept Videos
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:25Immunodeficiency Diseases
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
There are three main causes of immunodeficiency disorders...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...